{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

New MSIF Portuguese website

We are delighted to launch our Portuguese mini-WoMS language site.

read more

We're improving our website

We are improving and updating our English language website over the next month so we apologise for any broken or missing links you may encounter.

read more

back to top

Profile of the Month : January 2008

Sophie Froger

Age: 50
Country: France
Occupation: Former attorney
Year of diagnosis: 2000

"Each day can bring us a few tiny moments of intense happiness."

English Espanol Deutsch Italiano Russian

read more

back to top

Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody

The authors looked at the clinical features of people with MS and similar diseases in the presence of a particular antibody (called AQP4, associated with neuromyelitis optica) in a Japanese population. They found that these antibodies are markers of extensive spinal cord involvement and frequent exacerbations.

authors: Tanaka M, Tanaka K, Komori M, Saida T.

source: J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):990-2

read more

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

The authors make estimates of the effectiveness of disease-modifying drugs in delaying disability progression in people with MS using a modeling technique. They found that they are generally effective in this respect but more effective in relapsing-remitting than in secondary progressive MS.

authors: Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

source: Neurology. 2007 Aug 15

read more

Health-related quality of life in multiple sclerosis: effects of natalizumab

The authors looked at the health-related quality of life of people with MS, and its relationship with natalizumab, a recently introduced treatment for MS. They found that quality of life, as reported in the study questionnaires, was reduced in MS, correlated with disability and was improved by natalizumab.

authors: Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

source: Ann Neurol. 2007 Aug 14

read more

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

This preliminary clinical trial studied safety and tolerability of a DNA vaccine in a small group of people with MS. It found that this treatment is safe and well tolerated, and reduces the number of auto-reactive antibodies as well as the number of inflammatory lesions visible on MRI scans.

authors: Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H

source: Arch Neurol. 2007 Aug 13

read more

back to top

Results published on BHT-3009, experimental DNA vaccine treatment for MS

source: US National MS Society

More details from the US National MS Society on the DNA vaccine study.

read more

Epidemiology of MS study in Ireland

source: MS Ireland

People with MS are being asked to help a new research project into the disease in Ireland.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.